Literature DB >> 24421498

Tofacitinib.

Dennis J Cada1, Kendra Demaris2, Terri L Levien3, Danial E Baker4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The May 2013 monograph topics are ado-trastuzumab emtansine, pomalidomide, mipomersen, pasireotide diaspartate, and glycerol phenylbutyrate. The DUE/MUE is on atypical antipsychotics, extended release.

Entities:  

Year:  2013        PMID： 24421498      PMCID： PMC3839465          DOI： 10.1310/hpj4805-413

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  16 in total

1.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Authors:  Joel M Kremer; Bradley J Bloom; Ferdinand C Breedveld; John H Coombs; Mark P Fletcher; David Gruben; Sriram Krishnaswami; Rubén Burgos-Vargas; Bethanie Wilkinson; Cristiano A F Zerbini; Samuel H Zwillich
Journal:  Arthritis Rheum       Date:  2009-07

2.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

Review 4.  Promising new treatments for rheumatoid arthritis - the kinase inhibitors.

Authors:  Yusuf Yazici; Alexandra L Regens
Journal:  Bull NYU Hosp Jt Dis       Date:  2011

5.  Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  Yoshiya Tanaka; Makoto Suzuki; Hiroyuki Nakamura; Shigeyuki Toyoizumi; Samuel H Zwillich
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-08       Impact factor: 4.794

6.  Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Authors:  Kamran Ghoreschi; Michael I Jesson; Xiong Li; Jamie L Lee; Sarbani Ghosh; Jason W Alsup; James D Warner; Masao Tanaka; Scott M Steward-Tharp; Massimo Gadina; Craig J Thomas; John C Minnerly; Chad E Storer; Timothy P LaBranche; Zaher A Radi; Martin E Dowty; Richard D Head; Debra M Meyer; Nandini Kishore; John J O'Shea
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.

Authors:  Debra M Meyer; Michael I Jesson; Xiong Li; Mollisa M Elrick; Christie L Funckes-Shippy; James D Warner; Cindy J Gross; Martin E Dowty; Shashi K Ramaiah; Jeffrey L Hirsch; Matthew J Saabye; Jennifer L Barks; Nandini Kishore; Dale L Morris
Journal:  J Inflamm (Lond)       Date:  2010-08-11       Impact factor: 4.981

9.  Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.

Authors:  Nervin Lawendy; Sriram Krishnaswami; Rong Wang; David Gruben; Courtney Cannon; Suzanne Swan; Gary Chan
Journal:  J Clin Pharmacol       Date:  2009-04       Impact factor: 3.126

10.  Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients.

Authors:  Matthew M Hutmacher; Sriram Krishnaswami; Kenneth G Kowalski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-12-06       Impact factor: 2.745
View more
  7 in total

1.  Disseminated cryptococcosis by biological therapy: We must manage the risk

Authors:  Efraín Guillermo Sánchez; David Acosta; Juan Álvarez; Gabriela Sánchez; Julio García-Casallas
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

Review 2.  Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.

Authors:  Marco Infante; Nathalia Padilla; Rodolfo Alejandro; Massimiliano Caprio; David Della-Morte; Andrea Fabbri; Camillo Ricordi
Journal:  Medicina (Kaunas)       Date:  2022-04-21       Impact factor: 2.948

3.  Glucocorticoid receptor dimers control intestinal STAT1 and TNF-induced inflammation in mice.

Authors:  Marlies Ballegeer; Kelly Van Looveren; Steven Timmermans; Melanie Eggermont; Sofie Vandevyver; Fabien Thery; Karen Dendoncker; Jolien Souffriau; Jolien Vandewalle; Lise Van Wyngene; Riet De Rycke; Nozomi Takahashi; Peter Vandenabeele; Jan Tuckermann; Holger M Reichardt; Francis Impens; Rudi Beyaert; Karolien De Bosscher; Roosmarijn E Vandenbroucke; Claude Libert
Journal:  J Clin Invest       Date:  2018-06-25       Impact factor: 14.808

4.  An assessment of the current treatment landscape for rheumatology patients in Qatar: Recognising unmet needs and moving towards solutions.

Authors:  Samar Al Emadi; Mohammed Hammoudeh; Mohamed Mounir; Ruediger B Mueller; Alvin F Wells; Housam Aldeen Sarakbi
Journal:  J Int Med Res       Date:  2017-03-07       Impact factor: 1.671

5.  The Effects of Tofacitinib-Mediated Janus Kinase/Signal Transducers and Activators of the Transcription Signal Pathway Inhibition on Collagen Biosynthesis in Hepatic and Skin Fibroblast Cell Culture.

Authors:  Mehtap Şahİn; Hüseyin Aydin; Ahmet Altun; Mehmet Emin Derİn; Ali Şahİn
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

6.  Importance of Shared Treatment Goal Discussions in Rheumatoid Arthritis-A Cross-Sectional Survey: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed.

Authors:  Kelly D O'Neill; Kathryne E Marks; Pamela S Sinicrope; Cynthia S Crowson; Dana Symons; Elena Myasoedova; John M Davis
Journal:  ACR Open Rheumatol       Date:  2021-09-18

7.  Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.

Authors:  Ji-Sang Lee; Hyo-Sung Kim; Yong-Seob Jung; Hyeon-Gyeom Choi; So-Hee Kim
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.